503045-59-8

Basic information

• Product Name: 6-CHLORO-3-IODO (1H)INDAZOLE
• Synonyms: 6-CHLORO-3-IODO (1H)INDAZOLE;6-Chloro-3-Iodo-Indazole
• CAS NO: 503045-59-8
• Molecular Formula: C7H4ClIN2
• Molecular Weight: 278.48
• Mol File: 503045-59-8.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 391.5±22.0 °C(Predicted)
• Appearance: /
• Density: 2.156±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 10.86±0.40(Predicted)
• CAS DataBase Reference: 6-CHLORO-3-IODO (1H)INDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-CHLORO-3-IODO (1H)INDAZOLE(503045-59-8)
• EPA Substance Registry System: 6-CHLORO-3-IODO (1H)INDAZOLE(503045-59-8)

Safety Data

• Hazardous Substances Data: 503045-59-8(Hazardous Substances Data)

Usage

General Description

6-Chloro-3-Iodo (1H) Indazole is a synthetic compound categorized under the class of Indazoles, which are organic compounds containing an indazole, which is a bicyclic heterocycle of two nitrogen atoms and one oxygen atom fused to a benzene ring. Possessing both chloro and iodo substituents, this chemical has potential use in various research and development contexts due to its distinctive structure. The properties and potential applications of 6 chloro-3-iodo (1H) indazole depend on the specific reactions and interactions with other substances, which can be influenced by factors such as temperature, pressure, and pH. It should be handled with care as it may present safety and health hazards if not properly managed during usage, storage, and disposal.

Upstream product

• 698-25-9 6-chloro-1H-indazole 
• 95-79-4 5-chloro-2-methyl-benzenamine 
• 61072-56-8 4-chloro-2-fluorobenzaldehyde 

Downstream Products

• 717134-47-9 methyl 6-chloro-1H-indazole-3-carboxylate 
• 885278-30-8 6-chloro-1H-indazole-3-carbonitrile 
• 13097-04-6 6-chloro-3-phenyl-1H-indazole 

Relevant articles and documents

Synthesis and Biological Evaluation of 3-Arylindazoles as Selective MEK4 Inhibitors

Herein we report the discovery of a novel series of highly potent and selective mitogen-activated protein kinase kinase 4 (MEK4) inhibitors. MEK4 is an upstream kinase in MAPK signaling pathways that phosphorylates p38 MAPK and JNK in response to mitogenic and cellular stress queues. MEK4 is overexpressed and induces metastasis in advanced prostate cancer lesions. However, the value of MEK4 as an oncology target has not been pharmacologically validated because selective chemical probes targeting MEK4 have not been developed. Optimization of this series via structure–activity relationships and molecular modeling led to the identification of compound 6 ff (4-(6-fluoro-2H-indazol-3-yl)benzoic acid), a highly potent and selective MEK4 inhibitor. This series of inhibitors is the first of its kind in both activity and selectivity and will be useful in further defining the role of MEK4 in prostate and other cancers.

Identification of novel inhibitors of Aurora A with a 3-(pyrrolopyridin-2-yl)indazole scaffold

A novel series of 3-(pyrrolopyridin-2-yl)indazole derivatives were synthesized and biologically evaluated for their anti-proliferative effects on five human cancer cell lines. As a result, all of them exhibited vigorous potency against HL60 cell line with IC50 values ranging from singe digital nanomolar to micromolar level. Besides, a majority of them displayed modest to good antiproliferative activities against the other four cell lines, including KB, SMMC-7721, HCT116, and A549. Particularly, compound 2y, as the most distinguished one in this series, demonstrated IC50 values of 8.3 nM and 1.3 nM against HL60 and HCT116 cell lines, respectively. Afterwards, for exploring the molecular target, compounds2d, 2g and 2y were further selected to evaluate the inhibitory activities against a panel of kinases. Finally, they were identified to be targeting Aurora A kinase with significant selectivity over other kinases, such as CHK1, CDK2, MEK1, GSK3β, BRAF, IKKβ and PKC.

PYRROLOPYRAZINE KINASE INHIBITORS

The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.